Peptide Research Evidence Center
Search any compound and get one standard screen: what it is, how it is thought to work, what human trials actually show, what only animal research shows, what has not been proven, its regulatory status, and the original sources behind every line.
Most-searched compounds
Full research pages for the three most-discussed metabolic compounds — trial results, evidence ratings, reality check, regulatory status and the original studies behind every line.
Semaglutide
Wegovy · Ozempic · Rybelsus
Approved — GLP-1 receptor agonist
STEP 1: −14.9% mean body weight at 68 weeks versus −2.4% with placebo
Open research profile →Tirzepatide
Zepbound · Mounjaro
Approved — dual GIP and GLP-1 receptor agonist
SURMOUNT-1: −20.9% mean body weight at 72 weeks in the highest studied group
Open research profile →Retatrutide
LY3437943
Investigational — triple receptor agonist, not FDA-approved
Phase 2: −24.2% mean body weight at 48 weeks in the highest studied group
Open research profile →Peptide Library
Every compound A–Z, filtered by category, research stage and mechanism.
Full peptide guide
The long-form editorial guide with printable PDFs for every compound.
Protocol tracker
Private protocol, dose calendar, site rotation, weight and symptom logging.
Questions answered
Dosing, safety, sourcing and legal-status questions in plain language.
Calculators
Reconstitution and syringe maths on the peptide page, plus calorie and body tools.
Research news
Reported trial results, new molecules and regulatory changes as they land.
Compare Peptides, the Clinical Trial Tracker, the Claim Checker and the Study Translator are being built next and will appear here as they go live.
38
Compounds profiled
17
With registered human trials
13
Preclinical or community-only
8 of these have an approved medicine somewhere in the world — and approval is always for a specific condition, not for general wellness use.
Three medicines, different evidence
Semaglutide and tirzepatide are approved prescription medicines. Retatrutide remains investigational. The chart below shows results from separate trials with different durations and participants, so it is a visual research snapshot — not a ranking or proof that one treatment is better for an individual.
Mean body-weight change
Selected obesity trials · published trial averages
Only semaglutide and tirzepatide have been compared directly: in the 72-week SURMOUNT-5 trial, mean change was −13.7% with semaglutide and −20.2% with tirzepatide. The trial was open-label and industry funded. There is no direct retatrutide comparison.
Single-receptor medicine
Evidence-backed strengths
Limits and trade-offs
Dual-receptor medicine
Evidence-backed strengths
Limits and trade-offs
Triple-receptor investigational compound
Evidence-backed strengths
Limits and trade-offs
Common effects across trials include nausea, diarrhoea, vomiting and constipation. Approved-product labels contain additional warnings and contraindications; individual suitability requires a prescriber.
Direct comparison: SURMOUNT-5, New England Journal of Medicine. Cardiovascular outcomes: SELECT, New England Journal of Medicine. Regulatory details: Wegovy label and Zepbound label.
Conclusions on this site come from primary sources only. Forums, social video and influencer posts are useful for spotting what people are claiming — they never establish a scientific conclusion.
Sourcing recommendation
For readers who need a vetted research-peptide supplier, we use Certiva Biologics. Their products are sold for research use only and are not for human consumption.
Certiva Biologics lists 99%+ purity and ships a Certificate of Analysis with every lot. Each batch is third-party tested, and the latest COA is available to review before ordering. They carry research peptides including tirzepatide, semaglutide and investigational retatrutide.
Visit www.certivabiologics.comTo view the peptide catalog, open the site menu and go to Member home.
This is our supplier of choice, not a medical recommendation. Research peptides are not approved for human consumption in many jurisdictions. Verify the latest COA, local regulations, and discuss any use with a qualified clinician.
